NYSEAMERICAN:BPMX - Biopharmx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.1725 -0.01 (-5.48 %) (As of 11/18/2018 11:25 AM ET)Previous Close$0.1725Today's Range$0.1725 - $0.1852-Week Range$0.10 - $0.38Volume1.24 million shsAverage Volume7.23 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California. Receive BPMX News and Ratings via Email Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CUSIPN/A Webwww.biopharmx.com Phone+1-650-8895020 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares191,520,000Market Cap$0.00 OptionableNot Optionable Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions What is Biopharmx's stock symbol? Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX." How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings data on Thursday, August, 30th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.02). The biotechnology company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.02 million. View Biopharmx's Earnings History. When is Biopharmx's next earnings date? Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, December 6th 2018. View Earnings Estimates for Biopharmx. What price target have analysts set for BPMX? 1 equities research analysts have issued twelve-month price targets for Biopharmx's shares. Their predictions range from $1.50 to $1.50. On average, they expect Biopharmx's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 769.6% from the stock's current price. View Analyst Price Targets for Biopharmx. What is the consensus analysts' recommendation for Biopharmx? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx. Has Biopharmx been receiving favorable news coverage? Headlines about BPMX stock have been trending somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biopharmx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. Are investors shorting Biopharmx? Biopharmx saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 11,838,037 shares, a decrease of 8.3% from the October 15th total of 12,916,364 shares. Based on an average daily trading volume, of 2,373,553 shares, the short-interest ratio is presently 5.0 days. Currently, 7.2% of the company's stock are short sold. View Biopharmx's Current Options Chain. Who are some of Biopharmx's key competitors? Some companies that are related to Biopharmx include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Biopharmx's key executives? Biopharmx's management team includes the folowing people: Ms. Anja B. Krammer, Co-Founder, Pres, Sec. & Director (Age 50)Mr. Greg Kitchener, Exec. VP & CFO (Age 47)Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 44)Dr. José Zayas, Sr. VP of OperationsDr. R. Kehl Sink, Sr. VP of Intellectual Property & Legal How do I buy shares of Biopharmx? Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biopharmx's stock price today? One share of BPMX stock can currently be purchased for approximately $0.1725. What is Biopharmx's official website? The official website for Biopharmx is http://www.biopharmx.com. How can I contact Biopharmx? Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020. MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 306MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: Why is Cost of Capital Important?